{"organizations": [], "uuid": "4cca3412e16a9ac1ecc2f3d176cfb2b440df7460", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180226.html", "section_title": "Archive News &amp; Video for Monday, 26 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-hemogenyx-pharmaceuticals-says-lea/brief-hemogenyx-pharmaceuticals-says-lead-candidate-shown-to-be-effective-in-treatment-of-leukemia-idUSASM000JQF", "country": "US", "domain_rank": 408, "title": "BRIEF-Hemogenyx Pharmaceuticals Says Lead Candidate Shown To Be Effective In Treatment Of Leukemia", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.085, "site_type": "news", "published": "2018-02-26T22:22:00.000+02:00", "replies_count": 0, "uuid": "4cca3412e16a9ac1ecc2f3d176cfb2b440df7460"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-hemogenyx-pharmaceuticals-says-lea/brief-hemogenyx-pharmaceuticals-says-lead-candidate-shown-to-be-effective-in-treatment-of-leukemia-idUSASM000JQF", "ord_in_thread": 0, "title": "BRIEF-Hemogenyx Pharmaceuticals Says Lead Candidate Shown To Be Effective In Treatment Of Leukemia", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "hemogenyx pharmaceuticals plc", "sentiment": "negative"}, {"name": "hemogenyx pharma plc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 26 (Reuters) - Hemogenyx Pharmaceuticals Plc:\n* HEMOGENYX PHARMA PLC - STMNT RE SHARE PRICE MOVEMENT\n* HEMOGENYX PHARMACEUTICALS - ‍CONFIRMS IT HAS FILED A PROVISIONAL PATENT APPLICATION RELATING TO COMPANY‘S DEVELOPMENT OF A NEW TYPE OF HUMANISED MICE\n* HEMOGENYX PHARMA- ‍FIRST DATA RESULTS HAVE SHOWN CDX BI-SPECIFIC ANTIBODIES ARE CAPABLE OF ATTACKING AND ELIMINATING BLOOD CANCER ACUTE MYELOGENOUS LEUKEMIA IN VITRO​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-26T22:22:00.000+02:00", "crawled": "2018-02-27T14:46:46.016+02:00", "highlightTitle": ""}